Cambridge, MA-based venture firm HealthCare Ventures and several other backers have invested $40.4 million in a Series C round of financing for Catalyst Biosciences, a South San Francisco developer of protein-based drugs for diseases such as hemophilia and cancer, according to a company statement. Morgenthaler Ventures, a Menlo Park, CA-based firm which says it has a Boston office, and Novartis BioVentures, of Cambridge and Basel, Switzerland, are among the other firms that participated in the financing.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
